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http://dx.doi.org/10.1016/j.jmii.2013Objectives: Stenotrophomonas maltophilia is a bacterial pathogen associated with health-
care associated infections, particularly in immunocompromised patients. Members of the
fluoroquinolone drug class are frequently used to treat S. maltophilia infection; however,
S. maltophilia resistance to fluoroquinolones, especially levofloxacin, has been increasing.
Methods: We sought to identify risk factors associated with levofloxacin resistance using a
case-control study. We examined sputum from 76 S. maltophilia-positive patients admitted
to our hospital between January 1, 2010 and June 30, 2011. Case groups were defined as pa-
tients who had S. maltophilia infections resistant to levofloxacin, and control groups were
defined as patients who had S. maltophilia infections susceptible to levofloxacin treatment.
Patient information including demographics, previous antibiotic use, and other traits weret of Medical Laboratory Medicine and Biotechnology, Yuanpei University, Hsin-Chu City, Taiwan;
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292 C.-J. Pien et al.recorded. In addition, S. maltophilia isolates from patient sputum were assessed for antibi-
otic resistance as well as for the presence of genes associated with drug resistance.
Results: Previous antibiotic treatment with first- or second-generation cephalosporin was
found more often in the levofloxacin-susceptible group; by contrast, previous piperacillin/ta-
zobactam treatment occurred more often in the levofloxacin-resistant group. Three genes
associated with drug resistance, including SmeA, SmeD, and SpgM were not significantly
different between these groups.
Conclusion: Piperacillin/tazobactam treatment is associated with subsequent isolation of
levofloxacin-resistant S. maltophilia from the respiratory tract.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Stenotrophomonas maltophilia is an aerobic glucose non-
fermentative Gram-negative bacillus ubiquitously present
in the environment. It has emerged as a pathogen in
healthcare associated infections (HAIs), especially in
immunocompromised patients.1e3
S. maltophilia has a variety of clinical presentations,
including bacteremia, respiratory tract infections, urinary
tract infections, skin and soft tissue infections, endo-
carditis, and meningitis.4e7 Respiratory tract infection,
especially ventilator-associated pneumonia, is most
frequently seen in S. maltophilia infections.8 Risk factors
associated with S. maltophilia colonization and infection
include hematologic malignancy, admission to intensive
care units, use of central venous catheters, recent surgery,
ventilator usage, and previous therapy with broad-
spectrum antibiotics, especially carbapenems.9e13
Many antibiotics, including carbapenems, are not
effective against S. maltophilia, making infections a chal-
lenge to treat.1,14 Trimethoprimesulfamethoxazole (TMP/
SMX) and levofloxacin are the most common antibiotics
used to treat the S. maltophilia infections; however, ac-
cording to the Taiwan Surveillance of Antimicrobial Resis-
tance program, resistance to ceftazidime, TMP/SMX,
levofloxacin, and ticarcillin/clavulanic acid has been
increasing.15e17 Antibiotic efflux pumps, such as SmeABC
and SmeDEF, have been reported to play a role in S. mal-
tophilia resistance to fluoroquinolones. In addition, SpgM, a
phosphoglucomutase, has also been associated with fluo-
roquinolone resistance in S. maltophilia.18,19
In this study, we assessed the roles of resistant genes for
efflux pumps and phosphoglucomutase for levofloxacin
resistance among clinical isolates of S. maltophilia. We also
evaluated the risk factors associated with levofloxacin
resistance in S. maltophilia infections using a caseecontrol
study.
Methods
Setting
The Hsin-Chu branch of the National Taiwan University
Hospital is a regional hospital with a capacity of 694 beds.
This was a case-control study.Bacterial isolates
We prospectively collected S. maltophilia isolated from the
respiratory tracts specimens of adult patients from January
1, 2010 to June 30, 2011 for this case-control study. If
several isolates of S. maltophilia were obtained from a
single patient, only the first to be isolated was included in
the study. Patients who were not admitted in our hospital
were excluded from the study. All of the isolates were
identified by conventional biochemical identification
methods and were confirmed by polymerase chain reaction
(PCR) analysis of the SM1 and SM4 regions of the S. malto-
philia 23S rRNA gene.20
Susceptibility testing
S. maltophilia is resistant to many drugs, including most
of penicillins, cephalosporins, and carbapenems, so we
focused on drugs commonly used to treat S. maltophilia
infections. Because our hospital does not stock them,
monobactam-class antibiotics were not used in this study.
Susceptibility to various antimicrobial agents, including
ciprofloxacin, TMP/SMX, tigecycline, and colistin were
determined by minimal inhibition concentrations using the
Clinical and Laboratory Standards Institute’s reference
microbroth dilution method.21
Case groups were defined as patients who had
levofloxacin-resistant S. maltophilia infections. Control
groups were defined as patients who had levofloxacin-
susceptible S. maltophilia infections. Patient medical re-
cords collected by chart review included age, sex, under-
lying disease, previous medical history, and previous
antibiotics usage. Previous antibiotics usage was defined as
administration of antibiotic less than 15 days prior to when
S. maltophilia was isolated from the patient’s sputum. Drug
resistant genes, such as SmeA, SmeD, and SpgM, were
analyzed in these bacteria by PCR analysis.18 Institutional
review board approval was obtained for this study (ethical
approval number HCGH99IRB-12).
Identification of SmeA, SmeD, and SpgM genes
Cells were prepared and inoculated onto a MuellereHinton
agar plate as in the agar dilution method. Following overnight
culture, cells were collected to make a 1.5 mL suspension of
Table 1 Basic data, underlying diseases, and risk factors of patients
Group Levofloxacin R Levofloxacin S p
N 25 51
Age 77.96  11.93 73.96  15.44 0.219
Male sex 18 (72) 31 (60.8) 0.539
DM 11(44) 12 (23.5) 0.068
ESRD 4 (16) 3 (5.9) 0.152
Malignancy history 3 (12) 6 (11.8) 0.976
COPD 10 (40) 14 (27.5) 0.269
Recent surgerya 3 (12) 13 (25.5) 0.175
Recent admissionb 5 (20) 11 (21.6) 0.875
Previous antibiotics
3rd generation cephalosporin 10 (40) 24 (47) 0.521
1st or 2nd generation cephalosporin 3 (12) 19 (37.3) 0.023
Augmentin 10 (40) 24 (47) 0.521
Piperacillin/tazobactam 12 (48) 13 (25.5) 0.05
Carbapenem 7 (28) 9 (17.6) 0.298
Quinolone 3 (12) 6 (11.8) 0.976
Aminoglycoside 2 (8) 4 (7.8) 0.981
Drug resistant genes
SmeA positive 6 (24) 15 (29.4) 0.62
SmeD positive 23 (92) 47 (92.2) 0.981
SpgM positive 23 (92) 44 (86.3) 0.468
Resistance to other antibiotics
Ciprofloxacin 21 (84) 2 (3.9) <0.005
TMP/SMX 9 (36) 5 (9.8) 0.006
Tigecycline 4 (16) 0 (0) 0.003
Colistin 20 (80) 24 (47.1) 0.006
a Recent surgery: surgery in the past 3 months.
b Recent admission: admission in the past month.
Data are presented as n (%).
COPD Z chronic obstructive pulmonary disease; DM Z diabetes mellitus; ESRD Z end-stage renal disease; TMP/SMX Z trimethoprim/
sulfamethoxazole.
Levofloxacin resistance in S. maltophilia 293optical density at 550 nm (OD550) Z 1.0. RNA was prepared
using an RNA-Be Kit (Tel-Test Inc., Friendswood, TX, USA) and
cDNAwasobtainedwith the SuperScript First-Strand Synthesis
System for reverse transcription-PCR (Invitrogen Corp.,
Carlsbad, CA, USA) using random hexamers. Primer pairs 50-
GTCGACCTGGTACAGCA-30/50-ACCTTAACCTGTGCCTTG-30, 50-
CCAAGAGCCTTTC CGTCAT-30/50-TCACGCTGAAGTCCGAGA-30
and 50-GTGACTTCGACC GTTGCTTC-30/50-ATCTTTTCCTTGAT
GAACGC-30 were used for PCR to detect the expression of
SmeA, SmeD, and SpgM, respectively, using cDNA of 16S rRNA
as an internal control.
Results
Eighty patients were originally recruited for this study.
Twenty-seven had levofloxacin-resistant S. maltophilia in-
fections. However, four patients were excluded because
they were not admitted to the hospital; two of these cases
demonstrated levofloxacin-resistance. Therefore, a total of
76 patients were enrolled in the study, 25 with levofloxacin-
resistant and 51 with levofloxacin-sensitive S. maltophilia
infections.
The basic demographic data, underlying diseases, and
other potential risk factors for patients in this study are
shown in Table 1. Previous antibiotic treatment with first-or second-generation cephalosporin was observed more
often in the levofloxacin-susceptible group; by contrast,
previous piperacillin/tazobactam use was reported more
often in the levofloxacin-resistant group.
Three drug resistance genes were analyzed in patient
bacterial isolates, including SmeA, SmeD, and SpgM (Table
1); however, no significant associations were found in
either group.
We also tested levofloxacin-resistant S. maltophilia for
resistance to other antibiotics. The results are shown in
Table 1. Similarly, several antibiotics, including ciproflox-
acin, TMP/SMX, tigecycline, and colistin had lower resis-
tance rates in bacteria sensitive to levofloxacin. Genes
associated with resistance towards other antibiotics are
shown in Table 2. Only TMP/SMX treatment showed
increased resistance rates in SmeD- and SpgM-negative
groups.
Discussion
Fihman et al22 reported that risk factors for S. maltophilia
infection include: immunocompromised status, central
venous catheter insertion in intensive care units, and hos-
pitalization within the previous 90 days. Other studies have
discussed risk factors for S. maltophilia bacteremia;
Table 2 Genes (SmeA, SmeD, SpgM) associated with
resistance towards other antibiotics
SmeA þ SmeA  p
N 21 55
Ciprofloxacin 5 (23.8) 18 (32.7) 0.449
TMP/SMX 4 (19.0) 10 (18.2) 0.931
Tigecycline 1 (4.8) 3 (5.5) 0.904
Colistin 11 (52.4) 33 (60) 0.547
SmeD þ SmeD  p
N 70 6
Ciprofloxacin 21 (30.0) 2 (33.3) 0.865
TMP/SMX 10 (14.3) 4 (66.7) 0.001
Tigecycline 3 (4.3) 1 (16.7) 0.192
Colistin 42 (60.0) 2 (33.3) 0.204
SpqM þ SpqM  p
N 67 9
Ciprofloxacin 20 (29.9) 3 (33.3) 0.831
TMP/SMX 9 (13.4) 5 (55.6) 0.002
Tigecycline 3 (4.5) 1 (11.1) 0.403
Colistin 41 (61.2) 3 (33.3) 0.1
TMP/SMX Z trimethoprim/sulfamethoxazole.
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tors for fluoroquinolone-resistant S. maltophilia in-
fections.23 In contrast to other studies, we did not find
underlying diseases to be a predisposing factor for
levofloxacin-resistant S. maltophilia infection. Although
patients with diabetes mellitus had a higher rate of
levofloxacin-resistant S. maltophilia infection, this rate
was not statistically significant.
Patients who had previously received piperacillin/tazo-
bactam antibiotic treatments had higher rates of levo-
floxacin resistance; however, previous use of first- or
second-generation cephalosporin had lower rates of levo-
floxacin resistance. The mechanism for resistance to levo-
floxacin after piperacillin/tazobactam use is unclear.
Further studies are necessary for better understanding of
the relationship between piperacillin/tazobactam treat-
ment and subsequent resistance to levofloxacin.
The levofloxacin-sensitive group was also sensitive to
other antibiotics, especially ciprofloxacin. In our study,
nearly all bacteria sensitive to levofloxacin also were sen-
sitive to ciprofloxacin, making it an alternative treatment
for S. maltophilia infection.24 S. maltophilia isolates
resistant to levofloxacin were also positive for genes asso-
ciated with drug resistance to other antibiotics.
A previous study reported that the SmeA, SmeD, and
SpgM genes are associated with multiple drugs resistance in
S. maltophilia.18 However, these observations were not
consistent with our data. SmeA, SmeD, and SpgM may play
minor roles in multiple drugs resistance of S. maltophilia,
or other mechanisms may have contributed to the drug
resistance of S. maltophilia found in our hospital. Further
testing is necessary to fully elucidate these mechanisms of
resistance.In the previous studies, S. maltophilia resistance to
TMP/SMX treatment has been associated with efflux pump
genes such as BpeEF-OprC.25 Although no study has yet
shown SpgM to be related to TMP/SMX resistance, our study
indicated that SMX-TMP resistance was associated with a
lower frequency of SmeD and SpgM. SmeD and SpgM may
not induce resistance to SMX/TMP, and other genes may
induce resistance to SMX/TMP. When SmeD and SpgM are
expressed, other genes related to SMX/TMP resistance may
be suppressed and thus decrease SMX/TMP resistance.
Our study had many limitations. Because the sample size
was small and all samples were from the same hospital,
many risk factors did not reach statistical significance.
Some genes commonly associated with drug resistance,
such as Smqnr, a gene associated with quinolone resistance
in some studies, were not detected in our study.26,27 We did
not find any genes associated with levofloxacin resistance in
our study.
In conclusion, except for previous piperacillin/tazo-
bactam antibiotic treatment, we found no significant as-
sociations between S. maltophilia drug resistance to
levofloxacin and other risk factors in our patients. Three
genes, including SmeA, SmeD, and SpgMdpreviously re-
ported to be associated with levofloxacin resistancedwere
not significantly associated with the resistant group in our
study. Other genes may contribute to levofloxacin resis-
tance. More studies including larger case numbers and more
drug resistant genes are necessary to understand fully the
causes and risk factors of drug resistance in S. maltophilia.Conflicts of interest
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